Vascepa is manufactured, developed, and commercialized by Amarin Corporation, a specialized biopharmaceutical company focused on the treatment and management of cardiovascular diseases. The active pharmaceutical ingredient, icosapent ethyl (which is a uniquely purified and stable omega-3 fatty acid derivative), undergoes a rigorous, patented multi-month manufacturing process designed to meet strict U.S. Food and Drug Administration standards. This specialized production method ensures the absolute consistency, purity, and clinical efficacy of the drug, preventing oxidation and spoilage. Amarin distributes Vascepa globally through its own commercial teams in major markets as well as via international commercial partnership agreements across select global territories.